Search clinical trials for: MK-0646

Total 1744 results

Merck Sharp & Dohme LLC

Withdrawn

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

HIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

HIV-1 Infection

Germany, Romania
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Treatment Resistant Depression

United States
Peloton Therapeutics, Inc.

Active, not recruiting

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, Recurrent

United States
Merck Sharp & Dohme LLC

Completed

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

Kidney Failure, Chronic | End-Stage Renal Disease

United States, Israel, Romania
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

HIV-1 Infection

Germany
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Terminated

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Melanoma

Spain, United States, Australia, France, Israel, Italy, South Africa, Switzerland
NYU Langone Health
National Institutes of Health (NIH); Alzheimer's Association; LiteCure LLC

Recruiting

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Alzheimer Disease | Mild Cognitive Impairment

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
Merck Sharp & Dohme LLC

Terminated

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

Nonalcoholic Steatohepatitis

Korea, Republic of, United States, Argentina, Australia, Canada, Chile, China, Colombia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Puerto Rico, Russian Federation, Spain, Sweden, Taiwan, ...
Peloton Therapeutics, Inc., a subsidiary of Merck...
National Institutes of Health (NIH)

Completed

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Von Hippel-Lindau Disease | Clear Cell RCC | ccRCC | VHL Gene Mutation | VHL Syndrome | VHL Gene Inactivation | VHL | Von Hippel | Von Hippel's Disease | Von Hippel-Lindau Syndrome, Modifiers of

United States
Merck Sharp & Dohme LLC

Completed

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

HIV-1 Infection

Germany
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Advanced or Metastatic Solid Tumors

Canada, Switzerland, United States
Merck Sharp & Dohme LLC

Recruiting

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Lung Neoplasms | Non-Small-Cell Lung Carcinoma

United States, Brazil, Canada, Chile, China, Guatemala, Hong Kong, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, Romania, Dominican Republic, Philippines, ... and more
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Advanced Solid Tumors

Canada, United States, Denmark, Israel, Switzerland
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
AbbVie

Active, not recruiting

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

Type 2 Diabetes Mellitus
Cubist Pharmaceuticals LLC

Completed

Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)

Renal Impairment | Healthy Volunteers
National Cancer Institute (NCI)

Completed

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Colorectal Neoplasms

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Respiratory Syncytial Virus Infection

United States, Argentina, Belgium, Canada, Chile, China, Colombia, Denmark, Finland, France, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Philippines, Poland, Romania, South Africa, Thailand, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

HIV-1 Infection
Merck Sharp & Dohme LLC

Recruiting

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Hodgkin Disease

United States, Australia, Canada, Germany, Israel, Italy
Merck Sharp & Dohme LLC

Completed

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) (GIANT)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

Hypertension
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

Dementia | Alzheimer's Disease
Stuart Mazzone
Melbourne Health; Merck Sharp & Dohme LLC; Monash University

Recruiting

Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough

Chronic Cough

Australia
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Major Depressive Disorder, Recurrent
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Schizophrenia

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Merck Sharp & Dohme LLC

Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lymphoma | Solid Tumors

United States, Korea, Republic of, France, Israel, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
Merck Sharp & Dohme LLC

Completed

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Non-alcoholic Fatty Liver Disease
National Cancer Institute (NCI)

Active, not recruiting

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Carcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States, Ireland
Merck Sharp & Dohme LLC

Completed

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

Advanced Solid Tumors

United States, Australia, Canada, Chile, China, France, Greece, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, South Africa, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

Advanced Cancer
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Hepatitis C

Search clinical trials for: MK-0646

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations